Molecular and immunohistologic analyses cannot reliably solve diagnostic variation of flat intraepithelial lesions of the urinary bladder

American Journal of Clinical Pathology

Volumn 134, Issue 6, 2010, Pages 862-872

  Murata, Shin Ichi ^a   Iseki, Masachika ^b   Kinjo, Mitsuru ^c   Matsuzaki, Osamu ^d   Moriuchi, Akira ^e   Ohtani, Hiroshi ^f   Sakurai, Takaki ^a   Satake, Tatsunari ^g   Tsuzuki, Toyonori ^h  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b Sasebo Kyosai Hospital   (Japan)

^c STEEL MEMORIAL YAWATA HOSPITAL   (Japan)

^d KIMITSU CHUO HOSPITAL   (Japan)

^e National Hospital Organization   (Japan)

^f Hakujyuji Hospital   (Japan)

^g Nagoya Ekisaikai Hospital   (Japan)

^h NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

Author keywords

Flat intraepithelial lesions; Fluorescence in situ hybridization; Immunohistochemistry; Observer variation; Urinary bladder

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYTOKERATIN 20; KI 67 ANTIGEN; PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER; CANCER DIAGNOSIS; CARCINOMA IN SITU; CLINICAL ARTICLE; CONTINUING EDUCATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DYSPLASIA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; MALE; MEDICAL EDUCATION; PATHOLOGIST; PRIORITY JOURNAL; RELIABILITY; URINARY TRACT CARCINOMA; URINARY TRACT TUMOR; UROTHELIUM;

AGED; AGED, 80 AND OVER; BIOPSY; CARCINOMA IN SITU; CARCINOMA, PAPILLARY; CARCINOMA, TRANSITIONAL CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KERATIN-20; KI-67 ANTIGEN; MALE; MIDDLE AGED; OBSERVER VARIATION; PRECANCEROUS CONDITIONS; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 78649642423     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPACNUDWEN9GN4     Document Type: Article

References (27)

1. Amin MB, Young RH. Intraepithelial lesions of the urinary bladder with a discussion of the histogenesis of urothelial neoplasia. Semin Diagn Pathol. 1997;14:84-97.
2. Eble JN, Sauter G, Epstein JI, et al, eds. WHO Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press; 2004:111-112.
3. Cheng L, Cheville JC, Neumann RM, et al. Flat intraepithelial lesions of the urinary bladder. Cancer. 2000;88:625-631. (Pubitemid 30056939)
4. Amin MB, McKenney JK. An approach to the diagnosis of flat intraepithelial lesions of the urinary bladder using the World Health Organization/International Society of Urological Pathology consensus classification system. Adv Anat Pathol. 2002;9:222-232.
5. Murphy WM, Grignon DJ, Perlman EJ. Tumors of the urinary bladder. In: Murphy WM, Grignon DJ, Perlman EJ, eds. Tumors of the Kidney, Bladder, and Related Urinary Structures. Washington, DC: Armed Forces Institute of Pathology; 2004.
6. Atlas of Tumor Pathology; Fourth Series, Fascicle 1.
7. Sun W, Zhang PL, Herrera GA. p53 protein and Ki-67 overexpression in urothelial dysplasia of bladder. Appl Immunohistochem Mol Morphol. 2002;10:327-331.
8. Mallofre C, Castillo M, Morente V, et al. Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia. Mod Pathol. 2003;16:187-191.
9. Varma M, Morgan M, Amin MB, et al. High-molecular-weight cytokeratin antibody (clone 34betaE12) as a urothelial marker: a note of caution [letter]. Histopathology. 2004;44:189-190.
10. Kunju LP, Lee CT, Montie J, et al. Utility of cytokeratin 20 and Ki-67 as markers of urothelial dysplasia. Pathol Int. 2005;55:248-254.
11. Raica M, Zylis D, Cimpean AM. Cytokeratin 20, 34betaE12 and overexpression of HER-2/neu in urine cytology as predictors of recurrences in superficial urothelial carcinoma. Rom J Morphol Embryol. 2005;46:11-15.
12. Yin H, He Q, Li T, et al. Cytokeratin 20 and Ki-67 to distinguish carcinoma in situ from flat non-neoplastic urothelium. Appl Immunohistochem Mol Morphol. 2006;14:260-265. (Pubitemid 44319050)
13. Bhatia A, Dey P, Kumar Y, et al. Expression of cytokeratin 20 in urine cytology smears: a potential marker for the detection of urothelial carcinoma. Cytopathology. 2007;18:84-86.
14. INK4 immunoreactivity is a reliable marker for urothelial carcinoma in situ. Hum Pathol. 2008;39:527-535.
15. Halling KC, King W, Sokolova IA, et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol. 2000;164:1768-1775.
16. Bubendorf L, Grilli B, Sauter G, et al. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol. 2001;116:79-86.
17. Schwarz S, Rechenmacher M, Filbeck T, et al. Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions [published online ahead of print August 10, 2007]. J Clin Pathol. 2008;61:2722-277. doi:10.1136/jcp.2007.049684.
18. Halling KC, Kipp BR. Bladder cancer detection using FISH (UroVysion assay). Adv Anat Pathol. 2008;15:279-286.
19. Nese N, Gupta R, Bui MH, et al. Carcinoma in situ of the urinary bladder: review of clinicopathologic characteristics with an emphasis on aspects related to molecular diagnostic techniques and prognosis. J Natl Compr Canc Netw. 2009;7:48-57.
20. Nguyen CT, Litt DB, Dolar SE, et al. Prognostic significance of nondiagnostic molecular changes in urine detected by UroVysion fluorescence in situ hybridization during surveillance for bladder cancer. Urology. 2009;73:347-350.
21. Murata S, Nakazawa T, Ohno N, et al. Conservation and alteration of chromosome territory arrangements in thyroid carcinoma cell nuclei. Thyroid. 2007;17:489-496.
22. Petraki CD, Sfikas CP. Review: non-papillary urothelial lesions of the urinary bladder: morphological classification and immunohistochemical markers. In Vivo. 2008;22:493-501.
23. Parker DC, Folpe AL, Bell J, et al. Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas. Am J Surg Pathol. 2003;27:1-10.
24. Cina SJ, Lancaster-Weiss KJ, Lecksell K, et al. Correlation of Ki-67 and p53 with the new World Health Organization/International Society of Urological Pathology Classification System for Urothelial Neoplasia. Arch Pathol Lab Med. 2001;125:646-651. (Pubitemid 32429812)
25. INK4a expression analysis as an ancillary tool for cytologic diagnosis of urothelial carcinoma. Am J Clin Pathol. 2009;132:776-784.
26. Daniely M, Rona R, Kaplan T, et al. Combined morphologic and fluorescence in situ hybridization analysis of voided urine samples for the detection and follow-up of bladder cancer in patients with benign urine cytology. Cancer. 2007;111:517-524.
27. Lotan Y, Bensalah K, Ruddell T, et al. Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. J Urol. 2008;179:2164-2169.